Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

4.0K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
Regulation of Metabolism01:19

Regulation of Metabolism

12.5K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
12.5K
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

5.4K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic Strategies for Hyperuricemia: From Small-Molecule Inhibitors to RNA Therapeutics.

ACS pharmacology & translational science·2026
Same author

Pulmonary surfactant camouflage lipid nanoparticles for efficient mRNA lung delivery.

Signal transduction and targeted therapy·2026
Same author

Mitochondrial Enzymes Mimetic Ultrasmall Palladium Nanozymes Prevent Senescence and Neurodegeneration Through Metabolic Reprogramming.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Rational Design of Spherical Nucleic Acids: Expanding Horizons for Precision Nucleic Acid Therapy.

ACS applied materials & interfaces·2026
Same author

Extracellular Vesicle-Based mRNA Therapeutics and Vaccines.

Exploration (Beijing, China)·2026
Same author

Carrier-Free Peptide-Daunorubicin-Small Interfering RNA Nanoassembly for Targeted Therapy of Acute Myeloid Leukemia.

Cyborg and bionic systems (Washington, D.C.)·2025

Related Experiment Video

Updated: Apr 11, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K

Combating VEGFA-siRNA-Induced Metabolic Reprogramming via Glucose Utilization Deprivation.

Lulu Zheng1, Shuai Guo1, Yingjixing Luo2

  • 1School of Life Science, School of Interdisciplinary Science, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|April 9, 2026
PubMed
Summary

This study introduces a novel nanoparticle (iVG128) that combines siRNA and glucose oxidase to deplete tumor energy sources. This synergistic approach enhances cancer treatment efficacy by inhibiting both aerobic and anaerobic glucose utilization.

Keywords:
VEGFA siRNAglucose oxidaseglutamine metabolismlipid nanoparticletumor metabolic reprogramming

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
09:20

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

4.4K

Related Experiment Videos

Last Updated: Apr 11, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
09:20

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

4.4K

Area of Science:

  • Biomedical Engineering
  • Cancer Therapeutics
  • Nanomedicine

Background:

  • Vascular endothelial growth factor (VEGF) inhibitors are limited by tumor adaptation through tricarboxylic acid (TCA) cycle restoration and increased glycolysis.
  • Targeting tumor energy metabolism presents a promising strategy to overcome resistance to anti-VEGF therapies.

Purpose of the Study:

  • To develop a synergistic nanotherapeutic strategy for cancer treatment by co-delivering VEGFA-targeting siRNA and glucose oxidase.
  • To enhance the efficacy of siRNA-based cancer therapy by simultaneously depleting both aerobic and anaerobic glucose utilization.

Main Methods:

  • Design and synthesis of an ionizable lipid nanoparticle (LNP) for co-encapsulation of siVEGFA and glucose oxidase (GOx).
  • In vitro evaluation of the LNP formulation (iVG128) on cellular energy production, angiogenesis, and mitochondrial function.
  • In vivo assessment of iVG128's antitumor activity in CT26 and patient-derived xenograft models using metabolomics and transcriptomics.

Main Results:

  • The optimal formulation, iVG128, effectively inhibited cellular energy production, suppressed microvessel formation, and induced persistent TCA cycle suppression.
  • iVG128 demonstrated superior antitumor efficacy (2.6-fold higher than Sorafenib) and significantly prolonged survival in preclinical tumor models.
  • Metabolomic and transcriptomic analyses revealed that iVG128 counteracted VEGF inhibition-induced metabolic compensation, enhanced apoptosis, and suppressed adaptive gene programs.

Conclusions:

  • iVG128 represents a versatile nanoplatform for co-delivering enzymatic and RNA therapeutics.
  • This strategy offers an effective approach for cancer treatment by comprehensively depleting tumor energy sources.
  • The developed nanoplatform holds potential for overcoming therapeutic resistance in cancer by targeting metabolic vulnerabilities.